In February 2024 Evaxion announced the “successful completion” of initial phases of a vaccine collaboration with MSD to combine “both organisations’ unique capabilities and know-how”. This update follows a statement last year that indicated that a novel pipeline programme, EVX-B3, had been initiated in partnership with an “undisclosed leading pharmaceutical company”. EVX-B3 is a vaccine candidate designed using novel targets against a bacterial pathogen that were identified with Evaxion’s proprietary platform, AI-Immunology.
EVX-B3 and AI-Immunology
EVX-B3 is a bacterial vaccine development project, executed in collaboration with MSD, to address a “pressing global medical issue” presented by an “undisclosed bacterial pathogen”, which currently has “no preventive or curative options”.
AI-Immunology is a “scalable and adaptable artificial intelligence technology platform” that is “at the forefront of vaccine discovery for infectious diseases and cancers”. It integrates the “collective power” of other proprietary models to model the complexity of the patient’s immune system.
“AI-Immunology advanced computational modelling swiftly and uniquely identifies, predicts, and designs vaccine candidates, revolutionising the landscape of immunotherapy by offering a holistic and personalised approach.”
Evaxion’s Chief Executive Officer, Christian Kanstrup, is “proud” to reveal that the “leading pharma company” that joined the collaboration is MSD.
“We are excited about the successful conclusion of the vaccine target discovery and design phases of the collaboration and are eagerly awaiting the next phase. We strongly believe that this collaboration will further validate the power of our AI-Immunology platform and contribute to improving lives by designing unique vaccines addressing serious medical conditions.”
Dr Tarit Mukhopadhyay, Vice President, Head of Infectious Diseases and Vaccine Discovery at MSD Research Laboratories is “excited” to “further advance” the collaboration with the Evaxion team.
“At MSD, we are exploring new ways to apply AI technologies across the discovery-development continuum.”
We’re looking forward to hearing more from representatives of both organisations at the Congress, including a showcase on the AI-Immunology platform – don’t forget to get your tickets to join us there and subscribe for more insights here.
